Cargando…
Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data
The A3 adenosine receptor (A3AR) is overexpressed in pathological human cells. Piclidenoson and namodenoson are A3AR agonists with high affinity and selectivity to A3AR. Both induce apoptosis of cancer and inflammatory cells via a molecular mechanism entailing deregulation of the Wnt and the NF-κB s...
Autor principal: | Fishman, Pnina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229414/ https://www.ncbi.nlm.nih.gov/pubmed/35744805 http://dx.doi.org/10.3390/molecules27123680 |
Ejemplares similares
-
Targeting the A(3) adenosine receptor to treat cytokine release syndrome in cancer immunotherapy
por: Cohen, Shira, et al.
Publicado: (2019) -
Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects
por: Fishman, Pnina, et al.
Publicado: (2023) -
Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A(3) Adenosine Receptor Agonist Piclidenoson
por: Cohen, Shira, et al.
Publicado: (2018) -
The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice
por: Fishman, Pnina, et al.
Publicado: (2019) -
Putative role of the adenosine A(3) receptor in the antiproliferative action of N(6)-(2-isopentenyl)adenosine
por: Blad, Clara C., et al.
Publicado: (2011)